2-甲基-3-叔丁基-1H-吲哚 | 59931-85-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-甲基-3-叔丁基-1H-吲哚
• 英文名称: 2-methyl-3-tert-butyl-1H-indole
• 英文别名: 3-tert-butyl-2-methylindole；3-tert-butyl-2-methyl-indole；2-Methyl-3-tert.-butyl-indol；2-Methyl-3-tert.-butylindol；3-tert-Butyl-2-methyl-indol；3-tert-butyl-2-methyl-1H-indole
• CAS: 59931-85-0
• 化学式: C₁₃H₁₇N
• 分子量: 187.285
• InChiKey: DPOBYUOBYKJOLR-UHFFFAOYSA-N

物化性质

• 熔点：
  48 °C
• 沸点：
  134-136 °C(Press: 0.5 Torr)
• 密度：
  1.013±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2-甲基-3-叔丁基-1H-吲哚 在 氧气 、 焦磷酸硫胺素 作用下， 以 氘代氯仿 为溶剂， 反应 2.0h， 生成 1-Acetyl-2-methyl-3-tert-butylindole-1,2-dioxetane
  参考文献：
  名称：

  Reactions of N-acylated indoles with singlet oxygen

  摘要：

  Reactions of seven N-acyl indole derivatives with singlet oxygen have been investigated. 1-Acetyl-(1a) and 1-(chloroacetyl)-2,3-dimethylindole (1b) gave exclusively 1-acetyl-(2a) and 1-(chloroacetyl)-2-hydroperoxy-3-methyleneindoline (2b), respectively, in high yields via ene reaction on irradiation with oxygen in the presence of TPP sensitizer. 1-Acetyl-3-methylindole (1c) gave only 1-acetyl-2-hydroperoxy-3-methyleneindoline (2c) in low yield under the same conditions. In contrast, 1-acetyl-2-methyl-3-ethylindole (3a) and 1-acetyl-2-methyl-3-isopropylindole (3b) gave a mixture of ene products, 2-hydroperoxy- and 3-hydroperoxyindolines (4a and b and 5a and b), in addition to 2,3-bond cleavage products 6a and 6b, respectively. In the case of 1-acetyl-2-methyl-3-tert-butylindole (7), only the product of 2,3-bond cleavage (8) was obtained. A 1,2-dioxetane is intermediate in the cleavage and could be observed after photooxygenation of 7 at -5-degrees-C by NMR and was reduced by trimethylphosphite and dimethyl sulfide. The decomposition rate constant of 1,2-dioxetane 10 was measured by NMR; E(a) is 24.6 kcal/mol.

  DOI：

  10.1021/jo00053a014
• 作为产物：
  描述：

  4,4-二甲基-2-戊酮 在 甲烷磺酸 、 4 A molecular sieve 、 phosphorus pentoxide 、 溶剂黄146 作用下， 以 甲苯 为溶剂， 反应 24.0h， 生成 2-甲基-3-叔丁基-1H-吲哚
  参考文献：
  名称：

  Regioselective Fischer indole route to 3-unsubstituted indoles

  摘要：

  Use of Eaton's reagent (P2O5/MeSO3H) as acid catalyst in the Fischer indole reaction using methyl ketones provides unprecedented regiocontrol to form the 3-unsubstituted indoles. In several instances where the harshness of the reagent causes decomposition and low yields, dilution in sulfolane or dichloromethane results in far less degradation and higher yields of indoles. Steric effects and the acidity of the medium are the two major factors that control the regioselectivity. The role of the P2O5 in the reagent mixture P2O5/MeSO3H is simply as a drying agent when used as catalyst for the Fischer indole reaction.

  DOI：

  10.1021/jo00009a014

文献信息

• BENZAZEPIN-2(1H)-ONE DERIVATIVES
  申请人：Boyle Jessica

  公开号：US20080103130A1

  公开（公告）日：2008-05-01

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are agonists at the beta-2 adrenoceptor. They are useful as feed additives for livestock animals.

  式(I)的化合物及其药用可接受的盐是β-2肾上腺素受体的激动剂。它们可用作家畜动物的饲料添加剂。
• Nickel-catalyzed Heteroannulation of<i>o</i>-Haloanilines with Alkynes
  作者：Yuji Yoshida、Takuya Kurahashi、Seijiro Matsubara

  DOI：10.1246/cl.2011.1067

  日期：2011.10.5

  A nickel-catalyzed heteroannulation has been developed where o-haloanilines react with alkynes to afford 2,3-disubstituted indoles. IPr (1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene) was found to be an effective ligand for the reaction.

  已开发一种镍催化的杂环合成反应，其中邻卤代苯胺与炔烃反应生成2,3-二取代吲哚。发现IPr（1,3-双(2,6-二异丙基苯基)咪唑-2-亚氮基）是该反应的有效配体。
• Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
  申请人：Baruah Anima

  公开号：US20070015758A1

  公开（公告）日：2007-01-18

  The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

  本发明提供了新的苄基胺化合物，包括苄基胺化合物的组合物，制备苄基胺化合物的方法，以及使用苄基胺化合物治疗或预防与脂蛋白代谢有关的各种疾病或症状的方法。
• Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use
  申请人：The University of British Columbia

  公开号：US10011573B2

  公开（公告）日：2018-07-03

  A compound having the structure of Formula I, wherein A is a substituted or unsubstituted aryl or heteroaryl group, D is a substituted or unsubstituted 5- or 6-membered heteroaryl or heterocyclyl group and E is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl group. The compounds are used for the treatment of androgen modulated indications including cancer (prostate, breast, ovarian, endometrial or bladder cancer), hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty and age related macular degeneration. The use of the compounds for the manufacture of a medicament for modulating AR activity, a method of treatment using such compounds and a pharmaceutical composition and a commercial package comprising said compounds are also described.

  具有式 I 结构的化合物，其中 A 是取代或未取代的芳基或杂芳基，D 是取代或未取代的 5 或 6 元杂芳基或杂环基，E 是取代或未取代的芳基、杂芳基、环烷基或杂环基。这些化合物可用于治疗雄激素调节适应症，包括癌症（前列腺癌、乳腺癌、卵巢癌、子宫内膜癌或膀胱癌）、脱发、痤疮、多毛症、卵巢囊肿、多囊卵巢病、性早熟和老年性黄斑变性。此外，还描述了这些化合物在制造调节 AR 活性的药物中的用途、使用这些化合物的治疗方法以及包含上述化合物的药物组合物和商业包装。
• 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
  申请人：Araxes Pharma LLC

  公开号：US10414757B2

  公开（公告）日：2019-09-17

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, G1, G2, L1, L2, m1, m2, n, X and E are as defined herein and, wherein at least one of R3a, R3b, R4a or R4b is not H. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  本研究提供了具有抑制 G12C 突变 KRAS 蛋白活性的化合物。这些化合物具有以下结构 (I)： 或其药学上可接受的盐、立体异构体或原药，其中 R1、R2a、R2b、R2c、R3a、R3b、R4a、R4b、R5a、R5b、R6、A、G1、G2、L1、L2、m1、m2、n、X 和 E 如本文所定义，其中 R3a、R3b、R4a 或 R4b 中至少有一个不是 H。还提供了与制备和使用此类化合物相关的方法、包含此类化合物的药物组合物以及调节G12C突变型KRAS蛋白活性以治疗疾病（如癌症）的方法。